Last reviewed · How we verify
Omega-3 Fatty Acid-Based Parenteral Nutrition
At a glance
| Generic name | Omega-3 Fatty Acid-Based Parenteral Nutrition |
|---|---|
| Also known as | trial |
| Sponsor | Huazhong University of Science and Technology |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Preoperative Fish Oil PN and Prognosis After Constipation Surgery
- Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients (PHASE2)
- Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy (PHASE2)
- Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis (PHASE2)
- Compassionate Use of Omegaven in Children (PHASE2, PHASE3)
- Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer (PHASE4)
- Application of n-3 Fatty to Patient of Jaundice
- Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: